GO:0050674 urothelial cell proliferation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050674 (urothelial cell proliferation) describes the multiplication of urothelial cells, the transitional epithelium lining the bladder, ureter, and renal pelvis.
• Loss of normal urothelial proliferation and cytoskeletal protein expression is linked to recurrent urinary tract infections and interstitial cystitis/bladder pain syndrome.
• In urothelial carcinoma, proliferation is driven by factors such as TGFB1I1, HNRNPU, VEGFA, and Runx2-dependent glutamine metabolism.
• MicroRNA-299-3p and natural compounds such as puerarin can suppress urothelial carcinoma cell proliferation and migration.
• Angiogenesis and endothelial cell proliferation accompany urothelial carcinoma progression, making vascular patterns a research focus.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to causally test genes regulating urothelial cell proliferation.
Description
Urothelial cell proliferation (GO:0050674) is the biological process by which urothelial cells multiply, expanding the transitional epithelial cell population that lines the bladder, ureter, and renal pelvis. This process is fundamental to maintaining the urothelial barrier and to repairing the epithelium after injury or infection. When urothelial proliferation is dysregulated, it contributes to both deficient barrier function in benign conditions and uncontrolled growth in urothelial carcinoma. Understanding the molecular drivers of urothelial cell proliferation is therefore central to urological research, from infection and chronic pain syndromes to bladder cancer. Recent studies have identified specific genes and pathways, including TGFB1I1, HNRNPU, VEGFA, and Runx2, that regulate proliferation in urothelial carcinoma models. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0050674, its mechanisms, key genes, disease relevance, and experimental methods.
urothelial cell proliferation At A Glance
| GO ID | GO:0050674 |
|---|---|
| GO term | urothelial cell proliferation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Multiplication of urothelial cells to expand the transitional epithelial population of the bladder, ureter, and renal pelvis |
| Anatomical location | Transitional epithelium of the bladder, ureter, and renal pelvis, external to the lamina propria |
| Related processes | Urothelial barrier maintenance, epithelial repair, urothelial carcinoma progression |
| Disease relevance | Recurrent urinary tract infections, interstitial cystitis/bladder pain syndrome, urothelial carcinoma |
What Is GO:0050674?
According to the Gene Ontology, GO:0050674 (urothelial cell proliferation) is defined as the multiplication or reproduction of urothelial cells, resulting in the expansion of a cell population. Urothelial cells make up a layer of transitional epithelium in the wall of the bladder, ureter, and renal pelvis, external to the lamina propria. In practical terms, this process encompasses the cell-cycle progression and division of urothelial cells that increases their number, as opposed to differentiation or apoptosis.
Why Is urothelial cell proliferation Important in Cell Biology?
Urothelial cell proliferation is essential for maintaining the integrity of the urinary tract barrier and for regenerating the urothelium after injury or infection. Deficits in urothelial cell proliferation and cytoskeletal protein expression have been observed in patients with recurrent and persistent urinary tract infections, suggesting that impaired proliferation contributes to disease chronicity. Similarly, decreased urothelial cytoskeleton and cell proliferation protein expression distinguishes interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation from other subtypes. Conversely, excessive or dysregulated urothelial cell proliferation is a hallmark of urothelial carcinoma, where genes such as TGFB1I1, HNRNPU, VEGFA, and Runx2 promote tumor growth. Therefore, understanding GO:0050674 is critical for developing diagnostics and therapeutics across benign and malignant urological diseases.
• Maintains the urothelial barrier that protects underlying tissues from urine components.
• Supports epithelial repair and regeneration after urinary tract infection or injury.
• Deficient urothelial proliferation is associated with recurrent and persistent urinary tract infections.
• Altered urothelial proliferation protein expression is linked to interstitial cystitis/bladder pain syndrome subtypes.
• Dysregulated proliferation drives urothelial carcinoma growth and progression.
• TGFB1I1 promotes proliferation and migration in urothelial carcinoma.
• HNRNPU targeting can overcome cisplatin resistance in bladder cancer, implicating proliferation control.
• Indoxyl sulfate promotes glutamine metabolism and proliferation in urothelial carcinoma via Runx2.
• MicroRNA-299-3p inhibits proliferation, motility, invasion, and angiogenesis via VEGFA in upper tract urothelial carcinoma.
• Puerarin inhibits bladder urothelial carcinoma cell proliferation and migration.
What Happens During urothelial cell proliferation?
Initiation of proliferation in response to stimuli
In simple terms: Urothelial cells start dividing when they receive growth signals or need to repair damage.
Urothelial cell proliferation is initiated in response to physiological demands such as epithelial repair after infection or injury, as well as pathological signals in cancer. In urothelial carcinoma, factors such as TGFB1I1 promote cell proliferation and migration, acting as a driver of tumor growth. Similarly, indoxyl sulfate stimulates glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2, linking metabolic stress to proliferative signaling. These stimuli activate intracellular pathways that push urothelial cells into the cell cycle.
Cell cycle progression and metabolic support
In simple terms: Once triggered, urothelial cells go through the cell cycle, supported by metabolic changes.
Proliferating urothelial cells require metabolic reprogramming to support rapid division. Indoxyl sulfate promotes glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2, indicating that glutamine utilization is important for sustaining proliferation. HNRNPU has been implicated in bladder cancer cisplatin resistance, and targeting it may affect proliferative capacity. These findings suggest that cell cycle progression in urothelial cells is tightly coupled to metabolic and RNA-processing pathways.
Regulation by microRNAs and signaling molecules
In simple terms: Small RNA molecules and growth factors can speed up or slow down urothelial cell division.
MicroRNA-299-3p inhibits cell proliferation, motility, invasion, and angiogenesis via VEGFA in upper tract urothelial carcinoma, demonstrating that microRNAs can suppress urothelial proliferation. VEGFA is a key angiogenic factor, and its inhibition by miR-299-3p reduces both proliferation and angiogenesis, linking urothelial proliferation to vascular support. Endothelial cell proliferation and vascular patterns in urothelial carcinoma further highlight the interplay between tumor cells and their vascular microenvironment.
Cytoskeletal and barrier function coupling
In simple terms: Proliferation is linked to the cytoskeleton and barrier proteins that keep the urothelium functional.
Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions have been observed in patients with recurrent and persistent urinary tract infections, indicating that proliferation is coordinated with cytoskeletal and barrier maintenance. Decreased urothelial cytoskeleton and cell proliferation protein expression also suggest that interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation might be different from other types of patients. Thus, urothelial proliferation is not an isolated event but is coupled to structural and barrier functions.
Pharmacological modulation of urothelial proliferation
In simple terms: Natural compounds and drugs can inhibit urothelial cell proliferation, which is useful in cancer research.
Puerarin, a natural compound, has been shown to inhibit bladder urothelial carcinoma cell proliferation and migration in comprehensive genomic analysis. This suggests that urothelial cell proliferation is a druggable process and that natural products can be used to study its regulation. Such studies provide insights into potential therapeutic strategies for urothelial carcinoma by targeting proliferative pathways.
Key Genes Involved in GO:0050674 urothelial cell proliferation
The following genes and proteins have been experimentally linked to urothelial cell proliferation in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1I1 | Promotes cell proliferation and migration in urothelial carcinoma | Potential therapeutic target in urothelial carcinoma |
| HNRNPU | RNA-binding protein involved in cisplatin resistance and proliferation | Targeting HNRNPU to overcome cisplatin resistance in bladder cancer |
| VEGFA | Angiogenesis and proliferation factor; target of miR-299-3p | Inhibition by miR-299-3p reduces proliferation, motility, invasion, and angiogenesis |
| Runx2 | Transcription factor mediating indoxyl sulfate-induced glutamine metabolism and proliferation | Links metabolic stress to urothelial carcinoma proliferation |
| MIR299 | MicroRNA-299-3p that inhibits proliferation via VEGFA | Suppresses upper tract urothelial carcinoma proliferation and angiogenesis |
| Puerarin (compound) | Natural compound inhibiting bladder urothelial carcinoma cell proliferation and migration | Pharmacological tool for proliferation studies |
| Cytoskeleton proteins | Structural proteins whose expression correlates with proliferation | Deficits linked to recurrent urinary tract infections |
| Barrier function proteins | Proteins maintaining urothelial barrier; co-regulated with proliferation | Deficits in recurrent and persistent urinary tract infections |
| Endothelial cell markers | Markers of angiogenesis and vascular patterns | Associated with urothelial carcinoma progression |
| Glutamine metabolism enzymes | Support metabolic needs of proliferating urothelial carcinoma cells | Indoxyl sulfate promotes glutamine metabolism via Runx2 |
| Cisplatin resistance mediators | Proteins contributing to chemoresistance | HNRNPU targeting overcomes cisplatin resistance |
| Migration-related proteins | Proteins involved in cell motility alongside proliferation | TGFB1I1 promotes migration and proliferation |
| Angiogenesis regulators | Factors controlling blood vessel formation | VEGFA and endothelial proliferation in urothelial carcinoma |
| Inflammation-related proteins | Proteins linking inflammation to proliferation | Implicated in interstitial cystitis/bladder pain syndrome |
| Urothelial differentiation markers | Markers distinguishing proliferative vs differentiated states | Used to assess urothelial cell proliferation deficits |
How Is urothelial cell proliferation Regulated?
Urothelial cell proliferation is regulated by multiple mechanisms, including microRNA-mediated suppression, metabolic signaling, and RNA-processing pathways. MicroRNA-299-3p inhibits proliferation, motility, invasion, and angiogenesis via VEGFA in upper tract urothelial carcinoma, demonstrating post-transcriptional regulation. Indoxyl sulfate promotes glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2, linking metabolic cues to proliferative gene expression. HNRNPU, an RNA-binding protein, is involved in cisplatin resistance and likely regulates proliferation-associated transcripts in bladder cancer. Additionally, TGFB1I1 promotes proliferation and migration, serving as a positive regulator in urothelial carcinoma. These pathways collectively control the balance between quiescence and proliferation in urothelial cells.
urothelial cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1I1 | Urothelial carcinoma proliferation and migration | Knockout or overexpression in urothelial carcinoma cell lines |
| HNRNPU | Bladder cancer cisplatin resistance | Knockout or point mutation to study chemoresistance |
| VEGFA | Upper tract urothelial carcinoma proliferation and angiogenesis | Knockdown or overexpression with miR-299-3p mimic |
| Runx2 | Indoxyl sulfate-induced proliferation and glutamine metabolism | Knockout or knock-in of Runx2 in urothelial carcinoma cells |
| Cytoskeleton/barrier proteins | Recurrent urinary tract infections and interstitial cystitis | Patient-derived urothelial cells or organoids |
Urothelial carcinoma
Urothelial carcinoma is characterized by dysregulated urothelial cell proliferation. TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma, making it a potential oncogenic driver. HNRNPU targeting can overcome cisplatin resistance in bladder cancer, linking proliferation-associated RNA processing to chemoresistance. Indoxyl sulfate promotes glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2, highlighting metabolic contributions to tumor growth. MicroRNA-299-3p inhibits proliferation, motility, invasion, and angiogenesis via VEGFA in upper tract urothelial carcinoma, suggesting a tumor-suppressive role. Puerarin inhibits bladder urothelial carcinoma cell proliferation and migration, indicating potential therapeutic avenues. Endothelial cell proliferation and vascular patterns are also altered in urothelial carcinoma, supporting the role of angiogenesis in disease progression.
Recurrent and persistent urinary tract infections
Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions have been observed in patients with recurrent and persistent urinary tract infections. This suggests that impaired urothelial proliferation contributes to the failure of the urothelium to regenerate and maintain a barrier against pathogens, leading to chronic infection.
Interstitial cystitis/bladder pain syndrome
Decreased urothelial cytoskeleton and cell proliferation protein expression suggest that interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation might be different from other types of patients. This indicates that urothelial proliferative defects may underlie specific subtypes of this chronic pain syndrome.
From urothelial cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFB1I1 reduce urothelial carcinoma proliferation? | CRISPR knockout of TGFB1I1 in urothelial carcinoma cell lines |
| Does HNRNPU mutation affect cisplatin sensitivity? | Point mutation or knockout of HNRNPU in bladder cancer cells |
| Can miR-299-3p overexpression suppress VEGFA-driven proliferation? | Knock-in or overexpression of miR-299-3p in upper tract urothelial carcinoma cells |
| Does Runx2 mediate indoxyl sulfate-induced proliferation? | Runx2 knockout or knock-in in urothelial carcinoma cells |
| Does puerarin inhibit proliferation via specific genes? | Overexpression or knockout models treated with puerarin |
| Are cytoskeletal deficits causal in recurrent UTI? | Knockout of cytoskeleton-related genes in urothelial organoids |
How to Study the urothelial cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| MTT/BrdU/EdU assay | Cell proliferation and DNA synthesis | Testing effects of genes or drugs on urothelial cell growth |
| RNA sequencing | Global gene expression changes | Identifying proliferation-associated pathways in urothelial carcinoma |
| qRT-PCR | Expression of specific genes/miRNAs | Validating microRNA-299-3p and VEGFA levels |
| Immunohistochemistry | Protein localization and expression in tissues | Assessing proliferation and cytoskeletal proteins in patient samples |
| Western blot | Protein expression levels | Detecting HNRNPU or Runx2 in urothelial cells |
| Wound healing assay | Cell migration | Evaluating TGFB1I1 or puerarin effects on motility |
| Transwell invasion assay | Cell invasion | Assessing invasive capacity of urothelial carcinoma cells |
| Tube formation assay | Angiogenesis | Measuring VEGFA-driven endothelial tube formation |
Cell proliferation assays
Standard proliferation assays such as MTT, BrdU, or EdU incorporation are used to measure urothelial cell proliferation in response to genetic or pharmacological perturbations. These assays quantify DNA synthesis or metabolic activity as proxies for cell division. They are commonly applied in urothelial carcinoma cell lines to test the effects of genes like TGFB1I1 or compounds like puerarin.
Gene expression and transcriptomic analysis
RNA sequencing and quantitative PCR are used to measure expression of proliferation-related genes and microRNAs in urothelial cells. For example, microRNA-299-3p and VEGFA expression can be quantified to assess their impact on proliferation. Transcriptomic profiling of patient-derived urothelial cells has revealed deficits in proliferation and cytoskeletal proteins in recurrent urinary tract infections and interstitial cystitis.
Protein expression and immunohistochemistry
Immunohistochemistry and Western blotting are used to detect proliferation markers and cytoskeletal proteins in urothelial tissues. These methods allow researchers to localize proliferating cells within the urothelium and correlate expression with disease states. Deficits in urothelial cell proliferation and barrier function proteins have been documented using such approaches.
Functional assays for migration and angiogenesis
Wound healing and transwell migration assays, as well as tube formation assays for angiogenesis, are used to study the functional consequences of altered urothelial proliferation. These methods complement proliferation assays by measuring motility and vascular support, which are often co-regulated with proliferation in urothelial carcinoma.
How CRISPR Can Be Used to Study GO:0050674 urothelial cell proliferation
Knockout
CRISPR knockout of genes such as TGFB1I1, HNRNPU, or Runx2 in urothelial carcinoma cell lines can determine whether these genes are required for urothelial cell proliferation. Knockout models enable loss-of-function studies to assess effects on proliferation, migration, and drug resistance. For example, targeting HNRNPU may reverse cisplatin resistance, linking proliferation control to chemosensitivity.
Point Mutation
Point mutations can be introduced into genes like HNRNPU or Runx2 to mimic clinically relevant variants or to disrupt specific functional domains. Such models help dissect which domains are critical for urothelial cell proliferation and downstream signaling. Point mutation knock-in can also be used to study resistance mechanisms in bladder cancer.
Knock-in
Knock-in of reporter genes or tagged alleles into proliferation-related loci allows real-time monitoring of gene expression and protein localization in urothelial cells. For instance, knocking in a fluorescent reporter under the control of the VEGFA promoter could track angiogenic signaling during proliferation. Knock-in models are valuable for studying dynamic regulation of urothelial proliferation.
Overexpression
CRISPR-mediated overexpression or cDNA overexpression of genes such as TGFB1I1 or microRNA-299-3p can test gain-of-function effects on urothelial cell proliferation. Overexpression of miR-299-3p is expected to suppress proliferation via VEGFA downregulation. Conversely, overexpression of TGFB1I1 may enhance proliferation and migration, providing insights into oncogenic mechanisms.
How EDITGENE Supports urothelial cell proliferation Research
Researchers studying urothelial cell proliferation-related genes often need to determine whether a candidate gene is causally involved in proliferation, migration, or drug resistance. EDITGENE provides CRISPR-based knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics services, to accelerate functional validation of genes implicated in GO:0050674.
Contact EDITGENE today to design your custom CRISPR model for urothelial cell proliferation research.
Frequently Asked Questions About urothelial cell proliferation
What is urothelial cell proliferation?
Urothelial cell proliferation (GO:0050674) is the multiplication or reproduction of urothelial cells, resulting in the expansion of a cell population. Urothelial cells form the transitional epithelium lining the bladder, ureter, and renal pelvis.
What genes are involved in urothelial cell proliferation?
Genes such as TGFB1I1, HNRNPU, VEGFA, and Runx2 have been experimentally linked to urothelial cell proliferation in urothelial carcinoma.
How is urothelial cell proliferation measured?
It is measured using proliferation assays such as MTT, BrdU, or EdU incorporation, as well as RNA sequencing and immunohistochemistry for proliferation markers.
What diseases are associated with abnormal urothelial cell proliferation?
Abnormal urothelial cell proliferation is associated with urothelial carcinoma, recurrent urinary tract infections, and interstitial cystitis/bladder pain syndrome.
What is the role of TGFB1I1 in urothelial carcinoma?
TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma, making it a potential therapeutic target.
How does microRNA-299-3p affect urothelial carcinoma?
MicroRNA-299-3p inhibits cell proliferation, motility, invasion, and angiogenesis via VEGFA in upper tract urothelial carcinoma.
What is the link between indoxyl sulfate and urothelial carcinoma proliferation?
Indoxyl sulfate promotes glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2.
Can puerarin inhibit bladder cancer cell proliferation?
Yes, puerarin has been shown to inhibit bladder urothelial carcinoma cell proliferation and migration in genomic analysis studies.
What is the role of HNRNPU in bladder cancer?
Targeting HNRNPU can overcome cisplatin resistance in bladder cancer, implicating it in proliferation and chemoresistance.
How can CRISPR be used to study urothelial cell proliferation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of specific genes in urothelial cell proliferation.
Conclusion
Urothelial cell proliferation (GO:0050674) is a fundamental biological process that maintains the urothelial barrier and contributes to the pathogenesis of urothelial carcinoma, recurrent urinary tract infections, and interstitial cystitis/bladder pain syndrome. Key genes such as TGFB1I1, HNRNPU, VEGFA, and Runx2 have been experimentally linked to proliferation, providing targets for further research. CRISPR-based models and functional assays are essential tools for dissecting the mechanisms of urothelial cell proliferation and for developing new therapeutic strategies.
References
- 1. Liang PI et al.. 2024. TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma.. Kaohsiung J Med Sci 40(3):269-279 PMID: 38180299
- 2. Adelmann TG et al.. 2024. Endothelial cell proliferation and vascular patterns in urothelial carcinoma.. Rom J Morphol Embryol 65(1):61-67 PMID: 38527985
- 3. Shi ZD et al.. 2022. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.. Mol Cancer 21(1):37 PMID: 35130920
- 4. Li JR et al.. 2025. Indoxyl sulfate promoted glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2.. Biomed Pharmacother 193:118865 PMID: 41337885
- 5. Wang CS et al.. 2024. MicroRNA-299-3p inhibits cell proliferation, motility, invasion and angiogenesis via VEGFA in upper tract urothelial carcinoma.. J Gene Med 26(1):e3616 PMID: 38049938
- 6. Jhang JF et al.. 2021. Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions in patients with recurrent and persistent urinary tract infections.. Low Urin Tract Symptoms 13(2):203-209 PMID: 33135375
- 7. Jhang JF et al.. 2021. Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation might be different from other types of patients.. Int J Urol 28(8):823-830 PMID: 33966299
- 8. Ma YY et al.. 2024. Comprehensive Genomic Analysis of Puerarin in Inhibiting Bladder Urothelial Carcinoma Cell Proliferation and Migration.. Recent Pat Anticancer Drug Discov 19(4):516-529 PMID: 37694778
